Marta Benavent

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

Marianne Pavel, David J. Gross, Marta Benavent et al. · Endocrine Related Cancer · 2018 · 135 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

Barbara Nuñez-Valdovinos, Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca et al. · The Oncologist · 2018 · 92 citations · Full text

Medicine, Oncology, Pathology +17

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

Rodrigo Dienstmann, Amita Patnaik, Rocio García‐Carbonero et al. · Cancer Discovery · 2015 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Ángela Lamarca et al. · Journal of Clinical Oncology · 2019 · 76 citations · Full text

Medicine, Endocrinology, Oncology +14

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

Sonia Molina‐Pinelo, Amancio Carnero, Fernando Rivera et al. · BMC Cancer · 2014 · 75 citations · Full text

Medicine, Bioinformatics, Oncology +17